Iridex Share Price (NASDAQ: IRIX)

$1.34

Last updated on August 30, 2025 at 1:26 am IST

$₹

Check the interactive Iridex Stock chart to analyse performance

Iridex stock performance

as on August 30, 2025 at 1:26 am IST

Today's Low:$1.34
Today's High:$1.40
$1.34
0.0%
Downside
Day's Volatility :4.29%
Upside
4.29%
52 Weeks Low:$0.78
52 Weeks High:$2.04
$1.34
41.64%
Downside
52 Weeks Volatility :61.67%
Upside
34.31%

Iridex Stock Returns

Period	Iridex Corp	Index (Russel 2000)
3 Months	34.5%	0.0%
6 Months	6.75%	0.0%
1 Year	-32.75%	0.0%
3 Years	-46.41%	-4.1%

Iridex Corp Key Stats

Check Iridex key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.34
Open	$1.4
Today's High	$1.4
Today's Low	$1.34
Market Capitalization	$22.8M
Today's Volume	$55.5K
52 Week High	$2.04
52 Week Low	$0.782
Revenue TTM	$49.7M
EBITDA	$-3.3M
Earnings Per Share (EPS)	$-0.32
Profit Margin	-10.95%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-105.72%

Stock Returns calculator for Iridex Stock including INR - Dollar returns

The Iridex stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Iridex investment value today

Current value as on today

₹72,284

Returns

₹27,716

(-27.72%)

Returns from Iridex Stock

₹33,000 (-33%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Iridex Stock

-31%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Iridex Stock from India on INDmoney has decreased by -31% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Iridex Corp

Name
Holdings %
Name
Holdings %
PARAGON Assoc & PARAGON Assoc II JV
5.95%
Vanguard Group Inc
3.48%
Renaissance Technologies Corp
2.25%
AMH Equity Ltd
1.13%
Geode Capital Management, LLC
0.79%
Citadel Advisors Llc
0.44%

Analyst Recommendation on Iridex Stock

Rating

Trend

Sell

0%Buy

50%Hold

50%Sell

Based on 6 Wall street analysts offering stock ratings for Iridex(by analysts ranked 0 to 5 stars)

Iridex Share Price Target

What analysts predicted

Upside of 49.25%

Target:

$2.00

Current:

$1.34

Iridex share price target is $2.00, a slight Upside of 49.25% compared to current price of $1.34 as per analysts' prediction.

Iridex Stock Insights

Price Movement
In the last 7 days, IRIX stock has moved up by 8.5%
Increasing Revenue
Revenue is up for the last 2 quarters, 11.89M → 13.57M (in $), with an average increase of 12.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -1.68M → -994.0K (in $), with an average increase of 69.6% per quarter
IRIX vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 62.1%
IRIX vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 161.7% return, outperforming this stock by 210.0%
Price to Sales
ForIRIX every $1 of sales, investors are willing to pay $0.5, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Iridex Corp Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$43.4M	↑ 1.99%
Net Income	$-8.8M	↓ 31.22%
Net Profit Margin	-20.28%	↑ 9.8%

	FY20	Y/Y Change
Revenue	$36.3M	↓ 16.34%
Net Income	$-6.3M	↓ 28.19%
Net Profit Margin	-17.41%	↑ 2.87%

	FY21	Y/Y Change
Revenue	$53.9M	↑ 48.3%
Net Income	$-5.2M	↓ 17.44%
Net Profit Margin	-9.69%	↑ 7.72%

	FY22	Y/Y Change
Revenue	$57.0M	↑ 5.69%
Net Income	$-7.5M	↑ 44.44%
Net Profit Margin	-13.25%	↓ 3.56%

	FY23	Y/Y Change
Revenue	$51.9M	↓ 8.96%
Net Income	$-9.6M	↑ 26.81%
Net Profit Margin	-18.45%	↓ 5.2%

	FY24	Y/Y Change
Revenue	$48.7M	↓ 6.17%
Net Income	$-8.9M	↓ 6.9%
Net Profit Margin	-18.31%	↑ 0.14%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$11.8M	↓ 5.59%
Net Income	$-3.5M	↑ 17.03%
Net Profit Margin	-29.45%	↓ 5.69%

	Q2 FY24	Q/Q Change
Revenue	$12.6M	↑ 7.4%
Net Income	$-2.7M	↓ 22.66%
Net Profit Margin	-21.21%	↑ 8.24%

	Q3 FY24	Q/Q Change
Revenue	$11.6M	↓ 8.31%
Net Income	$-1.9M	↓ 27.85%
Net Profit Margin	-16.69%	↑ 4.52%

	Q4 FY24	Q/Q Change
Revenue	$12.7M	↑ 9.63%
Net Income	$-834.0K	↓ 56.85%
Net Profit Margin	-6.57%	↑ 10.12%

	Q1 FY25	Q/Q Change
Revenue	$11.9M	↓ 6.3%
Net Income	$-1.7M	↑ 102.16%
Net Profit Margin	-14.17%	↓ 7.6%

	Q2 FY25	Q/Q Change
Revenue	$13.6M	↑ 14.08%
Net Income	$-994.0K	↓ 41.04%
Net Profit Margin	-7.32%	↑ 6.85%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$17.9M	↑ 2.68%

	FY20	Y/Y Change
Profit	$15.6M	↓ 13.27%

	FY21	Y/Y Change
Profit	$22.8M	↑ 46.75%

	FY22	Y/Y Change
Profit	$25.4M	↑ 11.11%

	FY23	Y/Y Change
Profit	$21.8M	↓ 14.04%

	FY24	Y/Y Change
Profit	$19.5M	↓ 10.57%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$4.4M	↓ 8.93%

	Q2 FY24	Q/Q Change
Profit	$5.2M	↑ 19.32%

	Q3 FY24	Q/Q Change
Profit	$4.3M	↓ 17.17%

	Q4 FY24	Q/Q Change
Profit	$5.6M	↑ 29.22%

	Q1 FY25	Q/Q Change
Profit	$5.1M	↓ 9.51%

	Q2 FY25	Q/Q Change
Profit	$4.6M	↓ 8.94%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-7.9M	↓ 21.07%
Investing Cash Flow	$-509.0K	↓ 38.45%
Financing Cash Flow	$-156.0K	↓ 101.5%

	FY20	Y/Y Change
Operating Cash Flow	$-3.2M	↓ 59.09%
Investing Cash Flow	$-93.0K	↓ 81.73%
Financing Cash Flow	$2.5M	↓ 1681.41%

	FY21	Y/Y Change
Operating Cash Flow	$8.2M	↓ 353.85%
Investing Cash Flow	$-5.6M	↑ 5874.19%
Financing Cash Flow	$9.5M	↑ 283.7%

	FY22	Y/Y Change
Operating Cash Flow	$-9.5M	↓ 215.85%
Investing Cash Flow	$-286.0K	↓ 94.85%
Financing Cash Flow	$-73.0K	↓ 100.77%

	FY23	Y/Y Change
Operating Cash Flow	$-6.7M	↓ 29.14%
Investing Cash Flow	$-109.0K	↓ 61.89%
Financing Cash Flow	$-5.0K	↓ 93.15%

	FY24	Y/Y Change
Operating Cash Flow	$-7.3M	↑ 8.01%
Investing Cash Flow	$-13.0K	↓ 88.07%
Financing Cash Flow	$2.6M	↓ 52200.0%

Q1 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-1.6M	↑ 68.34%
Investing Cash Flow	$-3.0K	↓ 109.37%
Financing Cash Flow	$0.0	↓ 100.0%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-3.1M	↑ 131.75%
Investing Cash Flow	$-1000.0	-
Financing Cash Flow	$2.8M	-

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-1.2M	↓ 59.71%
Investing Cash Flow	$-9.0K	↑ 800.0%
Financing Cash Flow	$-218.0K	↓ 107.72%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-1.1M	↓ 7.19%
Investing Cash Flow	$-11.0K	↑ 22.22%
Financing Cash Flow	$6.0M	↓ 2870.18%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-397.0K	↓ 65.45%
Investing Cash Flow	$-13.0K	↑ 18.18%
Financing Cash Flow	$-14.0K	↓ 100.23%

Iridex Technicals Summary

Sell

Neutral

Buy

Iridex is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Iridex Corp Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Iridex Corp	5.08%	6.75%	-32.75%	-46.41%	-32.07%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	4.24%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Iridex Corp	NA	NA	-0.44	0.0	-1.06	-0.07	NA	0.0
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Iridex Corp	Sell	$22.8M	-32.07%	NA	-10.95%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

About Iridex Corp

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Organization	Iridex
Employees	93
CEO	Mr. Patrick Mercer
Industry	Health Technology

Key Management of Iridex Corp

Name	Title
Mr. Scott A. Shuda J.D.	Executive Chairman
Mr. Patrick Mercer	CEO, President & Director
Mr. Bassem BouHabib	Vice President of International Sales
Mr. Romeo R. Dizon	Chief Financial Officer
Ms. Leigh Salvo	Head of Investor Relations

Important FAQs about investing in IRIX Stock from India :

What is Iridex share price today?

Iridex share price today is $1.34 as on August 30, 2025 at 1:26 am IST at the close of the market. Iridex share today touched a day high of $1.40 and a low of $1.34.

What is the 52 week high and 52 week low for Iridex share?

Iridex share touched a 52 week high of $2.04 and a 52 week low of $0.78. Iridex stock price today i.e. August 30, 2025 at 1:26 am IST is closed at $1.34, lower by 34.31% versus the 52 week high.

How to invest in Iridex Stock (IRIX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Iridex on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Iridex Shares that will get you 1.1194 shares as per Iridex share price of $1.34 per share as on August 30, 2025 at 1:26 am IST.

What is the minimum amount required to buy Iridex Stock (IRIX) from India?

Indian investors can start investing in Iridex (IRIX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Iridex stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Iridex share’s latest price of $1.34 as on August 30, 2025 at 1:26 am IST, you will get 7.4627 shares of Iridex. Learn more about fractional shares .

What are the returns that Iridex has given to Indian investors in the last 5 years?

Iridex stock has given -32.07% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?